Published in Curr Pharm Des on January 01, 2004
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08
Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.66
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother (2008) 1.58
The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol (2009) 1.53
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother (2010) 1.49
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med (2012) 1.32
Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry (2006) 1.27
New small-molecule synthetic antimycobacterials. Antimicrob Agents Chemother (2005) 1.23
Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J Med Chem (2005) 1.15
Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem (2009) 1.15
Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg Med Chem Lett (2007) 1.11
Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother (2006) 1.09
The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol (2010) 1.03
Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 0.99
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett (2008) 0.96
Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure (2012) 0.94
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem (2011) 0.93
Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem (2011) 0.93
Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 0.93
Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J (2008) 0.91
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J (2011) 0.91
Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorg Med Chem (2008) 0.90
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis. Antimicrob Agents Chemother (2013) 0.89
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro. J Med Chem (2013) 0.87
Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 0.83
Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PLoS One (2014) 0.83
Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents. Antimicrob Agents Chemother (2014) 0.79
Molecular insights into the binding of coenzyme F420 to the conserved protein Rv1155 from Mycobacterium tuberculosis. Protein Sci (2015) 0.79
Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs (2014) 0.79
Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis (2016) 0.78
Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents. ACS Med Chem Lett (2015) 0.77
New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther (2010) 0.77
Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. Antimicrob Agents Chemother (2006) 0.75
Design and Synthesis of Molecular Scaffolds with Anti-infective Activity. Tetrahedron (2016) 0.75
Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans. Antimicrob Agents Chemother (2016) 0.75
Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. J Antimicrob Chemother (2015) 0.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis (2005) 1.36
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One (2013) 1.31
Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol (2012) 1.30
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2012) 1.22
The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol (2010) 1.21
Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem (2009) 1.15
B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem (2004) 1.14
Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol (2012) 1.13
Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother (2006) 1.09
Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J Med Chem (2009) 1.04
Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS One (2012) 0.96
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett (2008) 0.96
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr): a review of the synthesis and biological evaluation of recent inhibitors. Curr Top Med Chem (2012) 0.95
Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the β' subunit of RNA polymerase. Mol Microbiol (2014) 0.93
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg Med Chem Lett (2011) 0.91
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J (2011) 0.91
Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J (2008) 0.87
Design of Potential Bisubstrate Inhibitors against Mycobacterium tuberculosis (Mtb) 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (Dxr)-Evidence of a Novel Binding Mode. Medchemcomm (2013) 0.83
Chemical genetics: an evolving toolbox for target identification and lead optimization. Prog Drug Res (2007) 0.80
Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria. PLoS One (2013) 0.80
C4-alkylthiols with activity against Moraxella catarrhalis and Mycobacterium tuberculosis. Bioorg Med Chem (2011) 0.79
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824. Bioorg Med Chem Lett (2010) 0.79
Quantification of small molecule organic acids from Mycobacterium tuberculosis culture supernatant using ion exclusion liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2006) 0.77
SYNTHESIS AND SPECTROSCOPIC DIFFERENTIATION OF 2- AND 4-ALKOXYTHIOTETRONIC ACIDS. Heterocycles (2004) 0.77
Novel route to 5-position vinyl derivatives of thiolactomycin: Olefination vs. deformylation. Tetrahedron Lett (2006) 0.77
Cyanovirin-N inhibits mannose-dependent Mycobacterium-C-type lectin interactions but does not protect against murine tuberculosis. J Immunol (2012) 0.76